Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 20/20 | 0.81 |
| ▸ | NR1I2 | O75469 | 6/20 | 0.81 |
| ▸ | PLK4 | O00444 | 1/20 | 0.81 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.81 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.81 |
| ▸ | JAK2 | O60674 | 1/20 | 0.81 |
| ▸ | ULK1 | O75385 | 1/20 | 0.81 |
| ▸ | ERN1 | O75460 | 1/20 | 0.81 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.81 |
| ▸ | ABL1 | P00519 | 1/20 | 0.81 |
| ▸ | KRAS | P01116 | 1/20 | 0.81 |
| ▸ | RAF1 | P04049 | 1/20 | 0.81 |
| ▸ | LCK | P06239 | 1/20 | 0.81 |
| ▸ | FYN | P06241 | 1/20 | 0.81 |
| ▸ | CDK1 | P06493 | 1/20 | 0.81 |
| ▸ | YES1 | P07947 | 1/20 | 0.81 |
| ▸ | LYN | P07948 | 1/20 | 0.81 |
| ▸ | MET | P08581 | 1/20 | 0.81 |
| ▸ | HCK | P08631 | 1/20 | 0.81 |
| ▸ | FGR | P09769 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14733911 | 0.95 | BRAF (0.73) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL1127795 | 0.93 | BRAF (0.70) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL1127075 | 0.91 | BRAF (0.68) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL11954894 | 0.90 | BRAF (0.82) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL31443429 | 0.90 | BRAF (0.66) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29353365 | 0.90 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL29350038 | 0.90 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| Dabrafenib SCHEMBL806377 | 0.90 | BRAF (1.00) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL3879259 | 0.89 | BRAF (0.66) | BRAFNR1I2PLK4EPHB6RIPK2 | |
| SCHEMBL9987536 | 0.89 | BRAF (0.67) | BRAFNR1I2PLK4EPHB6RIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994137-B | Darafil preparation method of nylon | 广州科锐特药业有限公司 | 2025-04-15 | — | — | CN | claimed |
| CN-118994137-A | Darafil preparation method of nylon | 广州科锐特生物科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| EP-4706770-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| WO-2025132388-A2 | A PROCESS FOR MAKING DABRAFENIB | SYNTHON B.V (NL) | 2025-06-26 | — | — | WO | disclosed |
| CN-118994137-B | Darafil preparation method of nylon | 广州科锐特药业有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-118994137-B | Darafil preparation method of nylon | 广州科锐特药业有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025072462-A1 | SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-118994137-A | Darafil preparation method of nylon | 广州科锐特生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994137-A | Darafil preparation method of nylon | 广州科锐特生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-08-15 | — | — | US | disclosed |
| EP-4397376-A2 | COMBINATION COMPRISING AN MEK INHIBITOR AND A B-RAF INHIBITOR | Novartis AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| WO-2011047238-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-2282636-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885NR1I2 886/4885PLK4 1205/4885 |
| US-20240269139-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION OF KINASES | TTK, MKNK1, MAP3K20 | BRAF 77/4885NR1I2 3757/4885PLK4 192/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885NR1I2 886/4885PLK4 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.